0001788028 2025-01-01 2025-12-31 0001788028 jspr:VotingCommonStockParValue00001PerShareMember 2025-01-01 2025-12-31 0001788028 jspr:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member 2025-01-01 2025-12-31 0001788028 2025-06-30 0001788028 2026-03-25 iso4217:USD shares 10-K/A true 2025-12-31 --12-31 2025 false 001-39138 JASPER THERAPEUTICS, INC. DE 84-2984849 2200 Bridge Pkwy Suite #102 Redwood City CA 94065 (650) 549-1400 Voting Common Stock, par value $0.0001 per share JSPR NASDAQ Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00 JSPRW NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 74800000 27996819 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">None.</p> Jasper Therapeutics, Inc. (“Jasper,” the “Company,” “we,” “our” or “us”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2026 (the “Original Form 10-K” and as amended, the “Annual Report”).The purpose of this Amendment is solely to disclose the information required in Part III (Items 10, 11, 12, 13 and 14) of Form 10-K, which information was previously omitted from the Original Form 10-K in reliance on General Instruction G(3) to Form 10-K. Accordingly, we hereby amend and restate in its entirety Part III of the Original Form 10-K.In addition, pursuant to the rules of the SEC, Item 15 of Part IV has been amended and restated in its entirety to include the currently dated certifications of the Company’s principal executive officer and principal financial officer required under Section 302 of the Sarbanes-Oxley Act of 2002. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. In addition, this Amendment does not include the certificate under Section 906 of the Sarbanes-Oxley Act of 2002 as no financial statements are being filed with this Amendment.Except as described above or as otherwise expressly provided by the terms of this Amendment, no other changes have been made to the Original Form 10-K. Except as otherwise indicated herein, this Amendment continues to speak as of the date of the Original Form 10-K, and we have not updated the disclosure contained therein to reflect any events that occurred subsequent to the filing date of the Original Form 10-K. This Amendment should be read in conjunction with the Original Form 10-K and with our filings with the SEC subsequent to the filing date of the Original Form 10-K. All capitalized terms used but not defined herein shall have the meanings ascribed to them in the Original Form 10-K. 0001788028 true FY